
    
      The study population will consist of 3 different groups: Group 1 - Stage 1 PCV13 naïve
      participants randomized within 3 sequential cohorts to ASP3772 or PCV13; Group 2 - Stage 2
      PCV13 naïve participants randomized within 3 sequential cohorts to ASP3772 or PCV13; and
      Group 3 - Stage 2 participants previously vaccinated with PCV13 that will receive PPSV23.
    
  